There is unmet need for the treatment of generalized pustular psoriasis (GPP) flares, according to a study published online Aug. 10 in JAMA Dermatology. Carla L. Zema, Ph.D., from Boehringer Ingelheim ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...
GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...
You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...
The US Food and Drug Administration (FDA) has approved spesolimab-sbzo, an interleukin (IL)-36 receptor antagonist, for the treatment of generalized pustular psoriasis (GPP) in adults and in pediatric ...
Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed, according to a study recently published online in ...
The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...
Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...
Please provide your email address to receive an email when new articles are posted on . An unmet need exists to treat generalized pustular psoriasis and its flares, leading many patients to seek ...
INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...
INGELHEIM, Germany--(BUSINESS WIRE)--The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorization* for Boehringer ...
Mark G. Lebwohl, MD, discusses how IL-36 mutations can play a part in disease presentation and how IL-17 and IL-23 pathways are more often implicated in plaque psoriasis. Aaron Farberg, MD, and Maria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results